PET Imaging of Tau Deposition in the Aging Human Brain.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neuron

• Publication date

  2016-03-02

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neuron.2016.01.028PMID 26938442PMCID PMC4779187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tau positron emission tomographic imaging in aging and early Alzheimer disease

  2016influential reference
• The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

  2015cited by this paper
• Pathological tau disrupts ongoing network activity.

  2015cited by this paper
• PART is part of Alzheimer disease

  2015cited by this paper
• Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy

  2015cited by this paper
• PART, a distinct tauopathy, different from classical sporadic Alzheimer disease

  2015influential reference
• Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue

  2015cited by this paper
• Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies.

  2015cited by this paper
• Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease

  2015cited by this paper
• The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

  2014cited by this paper
• Primary age-related tauopathy (PART): a common pathology associated with human aging

  2014influential reference
• Neural compensation in older people with brain β-amyloid deposition

  2014cited by this paper
• Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-β and Phosphorylated Tau

  2014cited by this paper
• Cerebrospinal Fluid Biomarkers Mirror Rate of Cognitive Decline

  2013cited by this paper
• Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

  2013cited by this paper
• Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies

  2013cited by this paper
• Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

  2013cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

  2013cited by this paper
• [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

  2013cited by this paper
• Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant

  2012influential reference
• Relation of neuropathology to cognition in persons without cognitive impairment

  2012cited by this paper
• Amyloid deposition, hypometabolism, and longitudinal cognitive decline

  2012cited by this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012influential reference
• Trans-Synaptic Spread of Tau Pathology In Vivo

  2012cited by this paper
• Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

  2012cited by this paper
• Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease

  2012cited by this paper
• Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

  2011cited by this paper
• Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

  2011influential reference
• Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging.

  2011cited by this paper
• Soluble tau Species, Not Neurofibrillary Aggregates, Disrupt Neural System Integration in a tau Transgenic Model

  2011cited by this paper
• Neuropathological alterations in Alzheimer disease.

  2011influential reference
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

  2010cited by this paper
• Age-associated cognitive decline.

  2009cited by this paper
• Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

  2009influential reference
• Alzheimer's Disease Neuroimaging Initiative

  2008cited by this paper
• Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium

  2008cited by this paper
• Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.

  2008cited by this paper
• Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

  2007cited by this paper
• Neuropathology of older persons without cognitive impairment from two community-based studies

  2006cited by this paper
• アルツハイマー病の早期診断に向けて-米国 Alzheimer's Disease Neuroimaging Initiative の取り組み

  2006cited by this paper
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006influential reference
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004influential reference
• Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

  2003cited by this paper
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

  2003cited by this paper
• Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease.

  2002cited by this paper
• Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease

  2002cited by this paper
• Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

  2001cited by this paper
• Alzheimer neuropathologic alterations in aged cognitively normal subjects.

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999influential reference
• Correction for partial volume effects in PET: principle and validation.

  1998influential reference
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease.

  1996cited by this paper
• Age, neurofibrillary changes, Aβ-amyloid and the onset of Alzheimer's disease

  1996cited by this paper
• Gentleman R: R: A language for data analysis and graphics

  1996influential reference
• Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital.

  1994cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• Observations on the brains of demented old people.

  1968cited by this paper
• Observations on the brains of non-demented old people.

  1968cited by this paper
• SWEDISH MEDICAL ASSOCIATION

  1959cited by this paper

• Dynamical Aβ-Tau-Neurodegeneration Model Predicts Alzheimer’s Disease Mechanisms and Biomarker Progression

  2026cites this paper
• Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer’s disease

  2026cites this paper
• Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum.

  2026cites this paper
• Sex-specific patterns in tau spreading throughout the Braak stages in the Alzheimer’s disease spectrum

  2026cites this paper
• Targeting tau in Alzheimer's Disease: rationale, approach and challenges.

  2026cites this paper
• Association of circulating proteasome activity with Alzheimer's pathology and cognitive functions in APOE ε4 carriers.

  2026cites this paper
• Implications of virus-induced stress granules in tauopathies

  2026cites this paper
• Multi-parametric longitudinal imaging of cerebral biomarkers in a rodent model of Alzheimer’s disease

  2026cites this paper
• Tau in Alzheimer's disease: Shaping the future patient journey

  2026cites this paper
• Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease

  2026cites this paper
• Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease.

  2026cites this paper
• Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

  2026cites this paper
• Graphical modeling of cortical tau pathology topography for its subtyping in Alzheimer’s disease

  2026cites this paper
• Tau PET imaging as a mediator between glymphatic dysfunction and cognitive decline: a cross-sectional and longitudinal study.

  2026cites this paper
• Global brain activity links subcortical degeneration to cortical tau progressively across Braak regions over early Alzheimer’s disease stages

  2026cites this paper
• Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults.

  2026cites this paper
• Free-water imaging predicts cognitive decline and clinical progression in cognitively normal older adults.

  2026cites this paper
• Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden

  2026cites this paper
• Linking dietary patterns to Alzheimer's disease biomarkers with network mathematical modeling could enable new approach methodologies in preventative AD research: a narrative interdisciplinary review

  2026cites this paper
• Characterizing amyloid and tau positron emission tomography‐based stages across the clinical continuum

  2026cites this paper
• Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.

  2026cites this paper
• Spatial patterns of tau accumulation across the Alzheimer's disease spectrum

  2026cites this paper
• CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis.

  2026cites this paper
• Disentangling on and off-target binding in flortaucipir PET: a voxel-to-voxel P-tau, ferric iron, and MAO-B histology-to-flortaucipir PET comparison

  2026cites this paper
• Aberrant medial entorhinal cortex dynamics link tau pathology to spatial memory impairment

  2025cites this paper
• Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology

  2025cites this paper
• Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis

  2025cites this paper
• In Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease

  2025cites this paper
• Pittsburgh Brain Health Initiative (BHI): protocol and methods for an observational study of cognitive function in former professional football players and controls

  2025cites this paper
• Evaluation of an in vivo biomarker of arteriolosclerosis (ARTS) and its associations with cognition and multimodal ATN(V) biomarkers in a cardiometabolic-risk enriched community cohort

  2025cites this paper
• Generalizable MRI normative modelling to detect age-inappropriate neurodegeneration

  2025cites this paper
• Patient-specific functional brain architecture explains cortical patterns of tau PET in Alzheimer’s disease

  2025cites this paper
• PET Head Motion Estimation Using Supervised Deep Learning With Attention

  2025cites this paper
• The potential of TDP-43 PET ligands for a biological diagnosis of TDP-43 proteinopathies

  2025cites this paper
• Microglia networks within the tapestry of alzheimer’s disease through spatial transcriptomics

  2025cites this paper
• Circadian rhythms are associated with higher amyloid-β and tau and poorer cognition in older adults

  2025cites this paper
• APOE genotype modulates the impact of sleep duration on locus coeruleus functional connectivity in pre-clinical Alzheimer’s disease

  2025cites this paper
• Defining the contributions of tau pathology in the amygdala to increasing depressive symptoms in aging

  2025cites this paper
• Using memory recall response time on digital cognitive testing to detect subtle cognitive changes among cognitively unimpaired older adults

  2025cites this paper
• Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-β and tau in patients with Alzheimer’s disease

  2025cites this paper
• Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

  2025cites this paper
• Tau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau

  2025cites this paper
• In Vivo Cortical Microstructure: Relationships With Tauopathy and Cognitive Impairment in the Elderly

  2025cites this paper
• REM Sleep Misfires: Intruding Delta Waves Forecast Tau, Amyloid, and Forgetting in Aging

  2025cites this paper
• Advances in PET imaging of protein aggregates associated with neurodegenerative disease

  2025cites this paper
• Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease

  2025cites this paper
• Comprehensive characterization of the transcriptional landscape in Alzheimer’s disease (AD) brains

  2025cites this paper
• Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer's disease.

  2025cites this paper
• Characterizing amyloid and tau PET-based stages across the clinical continuum

  2025cites this paper
• Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration

  2025cites this paper
• Neurodegeneration and aging: pathophysiology, diagnosis, and therapeutic targets

  2025cites this paper
• Primary age-related tauopathy

  2025cites this paper
• Structural and Molecular Imaging of Aging Brain: A Focus on MR Imaging and PET Modalities.

  2025cites this paper
• A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease

  2025cites this paper
• Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD

  2025cites this paper
• Developing a novel reference region for [18F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies

  2025cites this paper
• APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer’s disease

  2025cites this paper
• The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies

  2025cites this paper
• Activation of PPARα by gemfibrozil lowers tau-associated neuropathology in the MAPT mouse model of Alzheimer's disease.

  2025cites this paper
• Disrupted Brain Hierarchical Organization in Alzheimer’s Disease Progression

  2025cites this paper
• Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer’s disease in a multicenter and multiethnic aging population

  2025cites this paper
• Neuropathologically validated MRI to tau PET synthesis via Covariate-modulated attention networks

  2025cites this paper
• Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease

  2025cites this paper
• Entorhinal tau impairs short-term memory binding in preclinical Alzheimer’s disease

  2025cites this paper
• Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration

  2025cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer Disease

  2025cites this paper
• Prognostic Value of A/T/N Biomarkers

  2025cites this paper
• Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach.

  2025cites this paper
• Tau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology

  2025cites this paper
• Multimodal spatial gradients to explain regional susceptibility to fibrillar tau in Alzheimer's disease

  2025cites this paper
• Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease

  2025cites this paper
• Development and validation of global tau severity score in Alzheimer's disease using Florzolotau (18F) PET.

  2025cites this paper
• Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndrome

  2025cites this paper
• Exploring the origins of frequent tau-PET signal in vermal and adjacent regions

  2025cites this paper
• Alzheimer's disease cerebrospinal fluid biomarker levels and APOE genetic status are associated with hippocampal-cerebellar functional connectivity.

  2025cites this paper
• Key biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies

  2025cites this paper
• Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease

  2025cites this paper
• Divergent actions of physiological and pathological amyloid-β on synapses in live human brain slice cultures

  2025cites this paper
• Modifiable risk factor profiles moderate the effect of β-amyloid pathology on cognition in aging.

  2025cites this paper
• The Hallmarks of Ageing in Microglia

  2025cites this paper
• Multimodal and longitudinal characterization of distinct tau and atrophy clusters in Alzheimer’s disease spectrum

  2025cites this paper
• Establishing tau-PET cut-points for cognitive diagnosis with 18 F-PI-2620 in a multi-ethnoracial cohort

  2025cites this paper
• Examining the association between synaptic density and neurofibrillary tau among cognitively impaired and unimpaired older adults with and without Alzheimer's disease pathology

  2025cites this paper
• Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition.

  2025cites this paper
• Smartphone-based detection of memory decline in prodromal Alzheimer's disease

  2025cites this paper
• Patterns of pathological tau deposition reflect the dynamics of cortical brain activity

  2025cites this paper
• Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,170 people

  2025cites this paper
• Tau Pathology in the Medial Temporal Lobe and Neocortex: Implications for Cognitive Unimpaired in Cognitively Unimpaired Older Adults

  2025cites this paper
• Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease

  2025cites this paper
• Disease stage–specific atrophy markers in Alzheimer's disease

  2025cites this paper
• AdapDISCOM: An Adaptive Sparse Regression Method for High-Dimensional Multimodal Data With Block-Wise Missingness and Measurement Errors

  2025cites this paper
• Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles

  2025cites this paper
• Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models

  2025cites this paper
• Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2025cites this paper
• Investigating the neural network correlates of apathy, disinhibition, and executive dysfunction in active-duty United States Special Operations Forces

  2025cites this paper
• The absence of Parkin in hTau mice leads to synaptic mitochondrial dysfunction, alterations to the synaptic proteome, and increased phosphorylated tau in the Hippocampus

  2025cites this paper
• Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology

  2025cites this paper
• Rates of clinical progression according to biological Alzheimer's disease stages

  2025cites this paper
• Distribution of big tau isoforms in the human central and peripheral nervous system

  2025cites this paper
• Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.

  2025cites this paper